| 1 | Changed clinical aspects of primary liver cancer in China during the past 30 years显示文摘BACKGROUND: Primary liver cancer (PLC) is one of the most frequently seen tumors in China. Thirty years ago, patients with PLC were often detected at relatively late stage, with a palpable mass or marked clinical symptoms and poor prognosis. In the past 30 years, the diagnosis and treatment of PLC have been greatly improved with better prognosis. METHODS: In order to study the changes of PLC during the 30 years, the clinical data of 3250 patients with PLC from 10 medical institutions of China were collected, ana- lyzed , and compared with those of 3254 PLC patients be- fore the 30 years. RESULTS: In the 3250 patients aged 1-80 years, with an average age of 49.1 years, the male to female ratio (2.3:1) was lower than that before the 30 years. 73.5% of the 3250 patients sought medical advice within 3 months after the onset of the disease in contrast to 63.8% before the 30 years. Compared with those patients before the 30 years the symptoms and signs were alleviated generally. The HBsAg positive rate was 81.0%, but the HCV-Ab positive rate was 13.2%. The AFP level in 75% of patients was elevated, but in the remaining 25% was normal. 1912 patients (58.8%) were confirmed pathologically. Among them 1755 patients (91.8%) had hepatocellular carcinoma. The overall resec- tion rate was 46.3%. Those who had early, middle, late stage carcinoma accounted for 29.9%, 51.5%, and 18.6%respectively in contrast to 0.4%, 47.0%, and 52.6% repor- ted before the 30 years. The 1-, 3-, 5-year survival rates of the patients were 66.1%, 39.7%, and 32.5% respectively, whereas 93.5%, 70.1%, and 59.1% for the early stage pa- tients, and 65.3%, 30.5%, and 23.5% for the middle stage patients. The half and 1-year survival rates of the late stage patients were 52.5%, and 14.7%, respectively. CONCLUSION: Comparison with the clinical data before and after the 30 years show that PLC can be diagnosed ear- ly. More PLC patients tend to undergo resection while re- ceiving a better conservative treatment, which ensures a prognosis. | Bing-Hui Yang, Jing-Lin Xia, Li-Wen Huang, Zhao-You Tang, Ming-Shan Chen, Jin-Qing Li, An-Min Liang, Qin-Guo Mo, Hui-Shan Lu, Chao-Liu Dai, Lu-Nan Yan, Zhi-Jian Yu, Rong-Sheng Rao, Le-Qun Li, Zhi-Xiong Su, Zhuang-Wei Fang Shanghai, China Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai 200032, China Tumor Hospital, Zhongshan University, Guangzhou 510000, China Tumor Hospital, Guangxi Medical Universi- ty, Nanning 530000, China Xiehe Hospital, Fujian Medical University, Fuzhou 350000, China Second Hos- pital, Chinese Medical University, Shenyang 110000, China Huaxi Hospital, Sichuan University, Chengdu 610041, China Hospital Affiliated to Nantong Medical University, Nantong 226000 , China Second Hospital, Jiangxi Medical University, Nanchang 330000 , China First Hospital Affiliated to Guangxi Medical University, Nanning 530000 , China People’s Hospital of Hainan Province, Haikou 570000, China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，2： | 20 |
您所在的机构暂未开通此部分的功能，请联系管理员